6938 — Suzhou Ribo Life Science Share News
0.000.00%
Last trade - 00:00- HK$8.58bn
- HK$6.68bn
- CNY148.51m
Suzhou Ribo climbs on EU clinical trials application of RBD3133 for obesity
Brief: Suzhou Ribo Life Science Expects Revenue Of RMB311 Million-RMB436 Million For Six Months
Brief: Suzhou Ribo Life Science Says EMA Approves Initiation Of Phase 2B Trial Of Vortosiran
CEO Purchases 6800 H Shares On Open Market
CEO Purchases 13,200 H Shares Of Co
Suzhou Ribo jumps on first milestone achievement from Madrigal tie-up
Brief: Suzhou Ribo Life Science To Buy 25.93% Stake In Azemidite
Brief: Ribo Announces Strategic Collaboration with Insilico Medicine to Accelerate siRNA Drug Development Driven by AI
Brief: Suzhou Ribo Life Science Co Posts FY Loss Attributable RMB278.1 Million
Brief: Suzhou Ribo Life Science Says Phase III Clinical Trial Of RBD7022 Injection To Start In China
China's Suzhou Ribo Life Science jumps on Madrigal licensing deal
Madrigal, China's Suzhou Ribo sign license deal for liver‑disease programs (updated)
Madrigal, Suzhou Ribo in license deal for liver‑disease programs
Brief: Suzhou Ribo Life Science Signs Exclusive Worldwide Licensing Deal With Madrigal
Brief: Suzhou Ribo Life Science Says RBD5044 Injection Approved For Phase Ii Clinical Trial In China
Brief: Suzhou Ribo Life Science Announces Offer Price Of HK$57.97 Per Share Under Global Offering